Sartorius Stedim Biotech, a partner of the biopharma industry, completed the acquisition of BIA Separations, a Slovenian biotech company, for $422m. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," Dr. Joachim Kreuzburg, Chairman of the Board and CEO Sartorius Stedim Biotech.